Prati
Emmanuel S. Antonarakis, M.D.
Emmanuel S. Antonarakis, M.D.
Clark Endowed Professor of Medicine, University of Minnesota
Potvrđena adresa e-pošte na umn.edu - Početna stranica
Naslov
Citirano
Citirano
Godina
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
47872014
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
28372014
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402-1418, 2016
13512016
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ...
Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019
12552019
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ...
JAMA oncology 6 (5), 650-659, 2020
8702020
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
6892015
Ruthenium-based chemotherapeutics: are they ready for prime time?
ES Antonarakis, A Emadi
Cancer chemotherapy and pharmacology 66, 1-9, 2010
6452010
Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study
ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ...
Journal of Clinical Oncology 38 (5), 395-405, 2020
5732020
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ...
Molecular imaging and biology 17, 565-574, 2015
4922015
Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with …
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ...
Journal of Clinical Oncology 35 (19), 2149-2156, 2017
4452017
Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology
P Nuhn, JS De Bono, K Fizazi, SJ Freedland, M Grilli, PW Kantoff, ...
European urology 75 (1), 88-99, 2019
4172019
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?
KH Stopsack, LA Mucci, ES Antonarakis, PS Nelson, PW Kantoff
Cancer discovery 10 (6), 779-782, 2020
3882020
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ...
Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021
3562021
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study
AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ...
Journal of Clinical Oncology 37 (13), 1120-1129, 2019
3142019
The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up
ES Antonarakis, Z Feng, BJ Trock, EB Humphreys, MA Carducci, ...
BJU international 109 (1), 32-39, 2012
3132012
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
CJ Paller, ES Antonarakis
Drug design, development and therapy, 117-124, 2011
3112011
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ...
Molecular imaging and biology 18, 411-419, 2016
2652016
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study
MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ...
Science translational medicine 7 (269), 269ra2-269ra2, 2015
2632015
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions
CJ Paller, ES Antonarakis
Clinical advances in hematology & oncology: H&O 11 (1), 14, 2013
2422013
Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012
M Hussain, S Daignault-Newton, PW Twardowski, C Albany, MN Stein, ...
Journal of Clinical Oncology 36 (10), 991-999, 2018
2132018
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20